Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
2023; Massachusetts Medical Society; Volume: 388; Issue: 25 Linguagem: Inglês
10.1056/nejmoa2215943
ISSN1533-4406
AutoresJavier Bolaños‐Meade, Mehdi Hamadani, Juan Wu, Monzr M. Al Malki, Michael J. Martens, Lyndsey Runaas, Hany Elmariah, Andrew R. Rezvani, Mahasweta Gooptu, Karilyn Larkin, Brian C. Shaffer, Najla El Jurdi, Alison W. Loren, Melhem Solh, Aric C. Hall, Amin M. Alousi, Omer Jamy, Miguel‐Angel Perales, Janny M. Yao, Kristy Applegate, Ami S. Bhatt, Leslie S. Kean, Yvonne A. Efebera, Ran Reshef, W. B. Clark, Nancy DiFronzo, Eric Leifer, Mary M. Horowitz, Richard J. Jones, Shernan G. Holtan,
Tópico(s)Polyomavirus and related diseases
ResumoIn patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against graft-versus-host disease (GVHD). A phase 2 study indicated the potential superiority of a post-transplantation regimen of cyclophosphamide, tacrolimus, and mycophenolate mofetil.
Referência(s)